Surface Oncology
Cambridge
About Surface Oncology
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $88.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2020)
- Ticker: nasdaq:SURF
- Website: surfaceoncology.com
- Phone: (617) 714-4096
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/surface-oncology-147707 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.